(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

HHS Secretary Robert F. Kennedy Jr. places anti-vaxxers in control of U.S. vaccine policy, slandering an actual expert along ...

Artificial intelligence (AI) is no longer a distant innovation — it's now a core part of the pharmaceutical and life sciences ...

The US Supreme Court on Monday declined to review a federal appeals court decision that Merck Sharpe & Dohme Corp. couldn’t ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a ...

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILING Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

Amid a spate of high-profile investments in U.S. pharmaceutical production, two contract manufacturers are getting in on the ...